Lupus Nephritis: Activity, Chronicity, and Long-Term Care

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Biopsy activity and protein/kidney-function trends guide treatment; serology, class, and chronicity inform the decision but never supply a guaranteed prognosis.

Immune deposits and active injury guide classification. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Immune deposits and active injury guide classification. . Biopsy class, activity and chronicity answer different questions. Follow proteinuria and kidney function. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Detect kidney involvement

In SLE, follow creatinine/eGFR, urinalysis, and urine protein alongside BP and symptoms. New proteinuria, glomerular hematuria, or unexplained declining function requires assessment even if joint/skin disease is quiet. Complement and anti-dsDNA trends support evaluation but cannot diagnose a flare alone.

Decide when biopsy changes care

KDIGO uses proteinuria around ≥500 mg/day as a threshold to consider biopsy, with active sediment or unexplained falling function also important. Lesser proteinuria can still accompany active disease. Biopsy class, activity, chronicity, and vascular lesions guide treatment.

Active class III/IV ± V

Initial treatment combines glucocorticoids with a mycophenolic-acid regimen, low-dose IV cyclophosphamide, or appropriate combination therapy including belimumab or a CNI. Select according to severity, kidney function, fertility/pregnancy plans, infection risk, access, and the specific evidence—not class alone.

Pure class V differs

Low-level proteinuria often emphasizes supportive care and treatment of extrarenal lupus. Nephrotic proteinuria or its complications may justify immunosuppression. CNI trial eligibility and product precautions matter; an eGFR exclusion from one trial is not a universal contraindication to every CNI.

Measure renal response

Follow urine protein and kidney function serially, with BP, sediment, adherence, and toxicity. A common complete-response benchmark is protein <0.5 g/g with stable/improved kidney function, often assessed over 6–12 months; some patients respond later. This is not a guaranteed individual timetable.

Plan the long course

Use hydroxychloroquine unless contraindicated, plus indicated BP/proteinuria protection. Coordinate maintenance therapy, contraception or pregnancy planning, vaccination/infection prevention, and bone care. Unexpected worsening prompts assessment for nonadherence, infection, thrombosis, toxicity, or persistent activity; repeat biopsy can clarify.

Supporting evidence

Continue learning